All News

A new analysis showed a near 78% increase in citing safety concerns among parents with HPV vaccine hesitancy, contrary to no observed changes in serious adverse event reporting.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

The annual NIH-supported survey revealed changing substance use trends among college students and college-aged adults. Find key results for primary care in our quick slideshow.

Clinical decisions on LDL-C management currently rely on a measure at one time point, typically middle age. A new study suggests burden begins early and so should assessment.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

More than half of adults in every US state had either overweight or obesity in 2020. This at-a-glance slide show reports more findings from an annual compilation of public data.

Findings from a phase 3 clinical trial showed remdesivir reduced the risk of COVID-19-related hospitalizations by 87% in high-risk patients, the drug's manufacturer announced.

The Pfizer-BioNTech booster shot is authorized for use in persons aged ≥65 years, at high risk of severe disease, and who have frequent exposure to the virus increasing risk for severe infection.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

New hypertension research looks at stress hormones in early disease, the Quadpill as first Rx, tight BP control for older adults--for a start. We recap 8 new studies.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

A variety of exposures in the work environment can cause asthma in some employees, according to new research presented at ERS Virtual International Congress 2021.

Strong evidence from a large, real-world evidence study, and preliminary data from a phase 3 booster-dose trial may support J&J's next steps toward FDA authorization of a COVID-19 booster.

Data from the CDC on the Delta variant and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

In a new analysis of adults without immunocompromising conditions, vaccine effectiveness against hospitalization was higher for Moderna than Pfizer and Johnson & Johnson.

Pfizer/BioNTech report "robust" antibody response to COVID-19 vaccine in children aged 5 to 11 years with safety profile comparable to that seen in persons aged 16 to 25 years.

CCTA identified atherosclerosis in >40% of middle-aged adults without known coronary heart disease, report Swedish investigators; significant stenosis was found in another 5.2%.

Dapagliflozin adds substantial improvements in symptoms, exercise function to demonstrated disease-modifying properties for patients with HFpEF.